This was suggested by the differential effects of mutant EGFR versus mutant KRAS transduction in SCLC cells, where the latter induced more prominent changes and was associated with increased levels of phospho-ERK1/2 (Figure 1f). Here, KRAS is linked to small cell lung carcinoma.